由美国临床肿瘤学会(ASCO)、美国胃肠病学协会(AGA)、美国放射肿瘤学会(ASTRO)和美国肿瘤外科学会(SSO)共同主办的第20届美国临床肿瘤学会胃肠道肿瘤研讨会(ASCO GI 2023)将于当地时间2023年1月19日至21日以线上结合线下的形式举行,线下地点为美国旧金山Moscone West会展中心。
作为全球唯一且最为盛大的消化肿瘤年度学术会议,此次ASCO GI迎来了其20周年纪念日。
日前,ASCO官网发布了入选ASCO GI 2023的Poster题目,【肿瘤资讯】特此整理,让我们一睹中国学者的风采(以下排名不分先后)。
实体瘤
1. Abstract #352;Poster Bd #E13
题目:
A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant/refractory solid tumors
靶向claudin 18.2抗体偶联药物CMG901在耐药/难治性实体瘤患者中的1a期剂量递增、多中心试验
临床试验注册编号:NCT04805307
作者:中国广东,中山大学肿瘤防治中心徐瑞华教授团队
2. Abstract #368;Poster Bd #F9
题目:
Pyrotinib combined with SHR6390 in the treatment of refractory advanced HER2-positive gastric cancer or solid tumors: Safety and efficacy results from a phase Id trial
吡咯替尼联合SHR6390治疗难治性晚期HER-2阳性胃癌或其他实体瘤:一项Id期试验的安全性和疗效结果
临床试验注册编号:NCT03480256
作者:中国北京,北京大学肿瘤医院沈琳教授团队 Dan Liu
3. Abstract #382;Poster Bd #G4
题目:
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors
Q-1802(CLDN18.2/PD-L1 双抗)治疗复发或难治性实体瘤患者的首次人体1期研究的中期结果
临床试验注册编号:NCT04856150
作者:中国北京,北京大学肿瘤医院沈琳教授团队 Wang YK
4. Abstract #391;Poster Bd #G13
题目:
A multicenter, phase 1 study of AB011, a recombinant humanized anti-CLDN18.2 monoclonal antibody, as monotherapy and combined with capecitabine and oxaliplatin (CAPOX) in patients with advanced solid tumors
AB011(一种重组人源化抗CLDN18.2单克隆抗体)单药治疗vs.AB011联合卡培他滨和奥沙利铂(CAPOX)治疗晚期实体瘤患者的一项多中心、1期研究
临床试验注册编号:NCT04400383
作者:中国上海,同济大学附属东方医院李进教授团队
5. Abstract #799;Poster Bd #M14
题目:
Clinical efficacy and biomarker analysis of pucotenlimab (HX008) in patients with previously treated advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A single-arm, multicenter, phase 2 study
普特利单抗(HX008)在既往治疗过的晚期错配修复缺陷或微卫星高度不稳定的实体瘤患者中的临床疗效和生物标志物分析:一项单臂、多中心、2期研究
临床试验注册编号:NCT03704246
作者:中国北京,中国医学科学院肿瘤医院黄镜教授团队 Bo Zhang
6. Abstract #802;Poster Bd #M17
题目:
A phase Ⅱ clinical trial of toripalimab in advanced solid tumors with POLE/POLD1 mutation
特瑞普利单抗治疗晚期实体瘤伴POLE/POLD1突变的Ⅱ期临床试验
临床试验注册编号:NCT03810339
作者:中国广东,中山大学肿瘤防治中心徐瑞华教授团队 Ying Jin
7. Abstract #798;Poster Bd #M13
题目:
Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial
MIL93在晚期实体瘤患者中的安全性和初步疗效:1期试验的单药治疗部分
临床试验注册编号:NCT04671875
作者:中国北京,中国医学科学院肿瘤医院黄镜教授团队
结直肠癌
1. Abstract #125;Poster Bd #G3
题目:
Efficacy and safety of tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced colorectal cancer: A phase II, single-arm study
替雷利珠单抗联合西妥昔单抗和伊立替康在既往接受过治疗的RAS野生型晚期结直肠癌患者中的疗效和安全性:一项Ⅱ期单臂研究
临床试验注册编号:NCT05143099
作者:中国上海,复旦大学附属中山医院刘天舒教授团队 Xiaojing Xu
2. Abstract #132;Poster Bd #A2
题目:
Preoperative chemotherapy prior to primary tumor resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: A multicenter randomized controlled trial
无症状同步不可切除结直肠癌伴肝脏局限性转移的原发性肿瘤切除术前化疗:一项多中心随机对照试验
临床试验注册编号:NCT01307878
作者:中国上海,复旦大学附属中山医院许剑民教授团队 Qi Lin
3. Abstract #134;Poster Bd #G12
题目:
Efficacy and safety of neoadjuvant preoperative short-course radiation followed by envafolimab plus CAPEOX in microsatellite stable (MSS)/mismatch repair proficient (pMMR) locally advanced rectal cancer
新辅助术前短程放疗后恩沃利单抗联合CAPEOX治疗微卫星稳定(MSS)/错配修复完整(pMMR)局部晚期直肠癌的疗效和安全性
临床试验注册编号:NCT05216653
作者:中国浙江,浙江大学医学院附属邵逸夫医院黄学锋教授团队 Sheng Dai
4. Abstract #137;Poster Bd #G15
题目:
Updated results from ALTER-C001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC
ALTER-C001试验的更新结果:安罗替尼联合XELOX方案一线治疗转移性结直肠癌(mCRC)患者后序贯安洛替尼单药维持治疗的疗效和安全性
临床试验注册编号:ChiCTR1900028417
作者:中国四川,四川省肿瘤医院燕锦教授团队
5. Abstract #138;Poster Bd #G16
题目:
Updated results of ALTER-C002: Anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer.
ALTER-C002试验的更新结果:安罗替尼联合CAPEOX方案一线治疗 RAS/BRAF野生型不可切除转移性结直肠癌
临床试验注册编号:NCT04080843
作者:中国浙江,浙江大学医学院附属第二医院丁克峰教授、袁瑛教授团队
6. Abstract #150;Poster Bd #H9
题目:
Fruquintinib combined with tislelizumab and SBRT as a later-line therapy in microsatellite stability (MSS) metastatic colorectal cancer (mCRC): Results from the FRUIT trial
呋喹替尼联合替雷利珠单抗和立体定向放疗(SBRT)用于微卫星稳定型(MSS)转移性结直肠癌(mCRC)的后线治疗:FRUIT试验的结果
临床试验注册编号:NCT04924179
作者:中国武汉,华中科技大学同济医学院附属同济医院袁响林教授团队
7. Abstract #152;Poster Bd #H11
题目:
Efficacy and safety of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)
呋喹替尼联合mFOLFOX6/FOLFIRI方案作为晚期转移性结直肠癌(mCRC)一线治疗的疗效和安全性
临床试验注册编号:NCT05004441
作者:中国武汉,武汉大学中南医院周福祥教授团队
8. Abstract #156;Poster Bd #H15
题目:
Phase Ib study of dabrafenib, trametinib, irinotecan and cetuximab in BRAF V600E-mutated metastatic colorectal cancer
达拉非尼、曲美替尼、伊立替康和西妥昔单抗治疗BRAF V600E突变转移性结直肠癌的Ib期研究
临床试验注册编号:ChiCTR2200063316
作者:中国四川,四川省肿瘤医院林桐榆教授团队 陈永昌
9. Abstract #213;Poster Bd #L15
题目:
Patient-specific tumor-informed circulating tumor DNA (ctDNA) analysis for molecular residual disease (MRD) detection in surgical patients with stage I-IV colorectal cancer (CRC)
I-IV 期结直肠癌(CRC)手术患者中用于分子残留病灶(MRD)检测的患者个体化肿瘤知情(tumor-informed)循环肿瘤DNA(ctDNA)分析
作者:中国广东,中山大学肿瘤防治中心陈功教授团队 Di Cao
10. Abstract #236;Poster Bd # M18
题目:
Effect of CXCL1 on the NF-κB/P300 signaling pathway and colon cancer progression
CXCL1对NF-κB/P300信号通路和结肠癌进展的影响
作者:中国福建,福建省肿瘤医院卓长华教授团队
11. Abstract #24;Poster Bd #A19
题目:
Deep learning–assisted colonoscopy images for prediction of mismatch repair deficiency in colorectal cancer
深度学习辅助结肠镜图像预测结直肠癌的错配修复缺陷
作者:中国广东,中山大学附属第六医院邓艳红教授团队 胡健聪
12. Abstract #242;Poster Bd # N4
题目:
Effect of dynamic circulating tumor DNA minimal residual disease detection on recurrence surveillance and second resection rate after curative intent resection of colorectal liver metastasis: A prospective cohort study
循环肿瘤DNA(ctDNA)微小残留病灶(MRD)分析的动态变化对结直肠癌肝转移患者根治性切除术后复发监测和二次切除率的影响:一项前瞻性的队列研究
临床试验注册编号:ChiCTR2000035677
作者:中国上海,复旦大学附属肿瘤医院蔡三军教授团队 Yaqi Li
13. Abstract #26;Poster Bd #B1
题目:
A multicenter, case-control study of a novel multi-target fecal DNA test for colorectal cancer detection
一项新型多靶点粪便DNA检测结直肠癌的多中心病例对照研究
作者:中国广东,华大基因Jiaxi Peng等
14. Abstract #36;Poster Bd # B11
题目:
Sidedness and addition of chemotherapy associated with treatment outcomes of regorafenib for metastatic colorectal cancer (mCRC)
瑞戈非尼治疗转移性结直肠癌的疗效与原发肿瘤部位和加用化疗相关
作者:中国台湾,国立台湾大学医学院附设医院Tsung-Che Wu教授团队
15. Abstract #38;Poster Bd # B13
题目:
Emergence of RAS mutations in RAS wild type metastatic colorectal cancer patients receiving cetuximab as first-line treatment: A prospective study
接受西妥昔单抗一线治疗的RAS野生型转移性结直肠癌患者中出现RAS突变:一项前瞻性的研究
作者:中国台湾,高雄医学大学附设中和纪念医院Hsiang-Lin Tsai教授团队
16. Abstract #48;Poster Bd # C3
题目:
Tumor-informed patient-specific MRD monitoring analysis in colorectal cancer.
肿瘤知情(tumor-informed)的结直肠癌患者个体化微小残留病灶(MRD)监测分析
作者:中国广东,中山大学肿瘤防治中心陈功教授团队
胃食管癌
1. Abstract #300;Poster Bd #B19
题目:
A multiplex DNA methylation assay for noninvasive early detection of gastric cancer.
多重DNA甲基化检测在胃癌早期无创检测中的应用
作者:中国广东,基准医疗Weimei Ruan等
2. Abstract #310;Poster Bd #C9
题目:
Anlotinib plus PD-1 inhibitors as chemo-free therapy in advanced or metastatic esophageal cancer: Updated results from a retrospective real-world study
安罗替尼联合PD-1抑制剂“去化疗”治疗晚期或转移性食管癌:一项回顾性真实世界研究的更新结果
临床试验注册编号:NCT04966611
作者:中国河南,安阳市肿瘤医院洪永贵教授团队
3. Abstract #330;Poster Bd # D11
题目:
Early detection and localization of major gastrointestinal cancers by combining DNA methylation and fragmentomic signatures generated from a single cfDNA targeted sequencing assay
通过结合DNA甲基化和单一cfDNA靶向测序分析产生的片段组学特征,可早发现并定位大多数胃肠道肿瘤
临床试验注册编号:NCT05431621
作者:中国上海,复旦大学附属中山医院周俭教授团队 杨欣荣
4. Abstract #338;Poster Bd # D19
题目:
Role of pretreatment absolute lymphocyte count in survival outcomes for esophageal cancer treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort.
治疗前绝对淋巴细胞计数在接受新辅助化疗和帕博利珠单抗治疗的食管癌患者生存结局中的作用:一项前瞻性队列分析
临床试验注册编号:NCT04435197
作者:中国上海,上海交通大学医学院附属瑞金医院李鹤成教授团队 Weixiang Qi
5. Abstract #343;Poster Bd #E4
题目:
Nab-paclitaxel combined with oxaliplatin and S-1 as conversion therapy for advanced gastric adenocarcinoma
白蛋白结合型紫杉醇联合奥沙利铂和S-1方案转化治疗晚期胃腺癌
临床试验注册编号:NCT04047953
作者:中国北京,北京大学肿瘤医院季加孚教授团队 Ke Ji
6. Abstract #350;Poster Bd #E11
题目:
Two cycles versus four cycles of neoadjuvant camrelizumab plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, multicenter and randomized study
卡瑞利珠单抗联合化疗治疗局部晚期食管鳞状细胞癌(ESCC)患者,两周期与四周期治疗对比:一项前瞻性、多中心、随机研究
临床试验注册编号:ChiCTR2100051154
作者:中国江苏,江苏省肿瘤医院张勤教授团队
7. Abstract #353;Poster Bd #E14
题目:
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up.
纳武利尤单抗(NIVO)联合化疗(chemo)对比单纯化疗一线治疗晚期胃癌、胃食管交界处癌和食管腺癌(GC/GEJC/EAC)患者的疗效:CheckMate 649的中国亚组三年随访分析
临床试验注册编号:NCT02872116
作者:中国北京,北京大学肿瘤医院沈琳教授团队
8. Abstract #356;Poster Bd #E17
题目:
First-line of camrelizumab plus pyrotinib and chemotherapy in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A dose escalation and expansion phase I study.
卡瑞利珠单抗联合吡咯替尼和化疗一线治疗HER-2阳性进展期胃或胃食管交界处腺癌:一项剂量递增和剂量扩展队列的I期研究
临床试验注册编号:ChiCTR2000029717
作者:中国江苏,江苏省肿瘤医院朱梁军教授团队
9. Abstract #360;Poster Bd #F1
题目:
Preoperative camrelizumab combined with chemotherapy for borderline resectable esophageal squamous cell carcinoma (BRES-1): A single-arm, open-label, phase Ⅱ study.
术前卡瑞利珠单抗联合化疗治疗临界可切除食管鳞状细胞癌(BRES-1):一项单臂、开放标签、Ⅱ期研究
临床试验注册编号:ChiCTR2200056728
作者:中国河南,郑州大学第一附属医院李进东教授团队 Hang Yang
10. Abstract #363;Poster Bd #F4
题目:
SHR-1701 plus chemotherapy as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)
SHR-1701联合化疗一线治疗不可切除的局部晚期、复发性或转移性食管鳞状细胞癌(ESCC)
临床试验注册编号:ChiCTR2000039909
作者:中国山东,山东大学齐鲁医院程玉峰教授团队 Yi Wang
11. Abstract #364;Poster Bd #F5
题目:
PERSIST: A multicenter, randomized phase II trial of perioperative oxaliplatin and S-1 (SOX) with or without sintilimab in resectable locally advanced gastric/gastroesophageal junction cancer (GC/GEJC)
PERSIST:围手术期奥沙利铂和S-1(SOX)联合或不联合信迪利单抗治疗可切除的局部晚期胃/胃食管交界处癌(GC/GEJC),一项多中心、随机II期试验
临床试验注册编号:NCT04982939
作者:中国天津,天津医科大学肿瘤医院梁寒教授团队 丁学伟
12. Abstract #365;Poster Bd #F6
题目:
Camrelizumab plus low-dose apatinib and SOX in the first-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, dose escalation and expansion study (SPACE study).
卡瑞利珠单抗联合低剂量阿帕替尼和SOX一线治疗晚期胃/胃食管交界处(G/GEJ)腺癌:一项单臂、剂量递增和剂量扩展研究(SPACE研究)
临床试验注册编号:ChiCTR2000034109
作者:中国江苏, 江苏省人民医院陈晓锋教授团队
13. Abstract #366;Poster Bd #F7
题目:
Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment (NAT) for esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, phase Ⅱ clinical trial.
安罗替尼联合白蛋白结合型紫杉醇和顺铂新辅助治疗(NAT)食管鳞癌(ESCC):一项单臂、Ⅱ期临床试验的最新结果
作者:中国河南,安阳肿瘤医院张艳峰教授团队
14. Abstract #367;Poster Bd #F8
题目:
Preliminary results of TQB2450 (PD-L1 blockade) plus anlotinib combined with oxaliplatin and capecitabine in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, multicenter phase Ⅱ clinical trial.
TQB2450(PD-L1阻断剂)+安罗替尼+奥沙利铂+卡培他滨一线治疗晚期胃或胃食管交界处(G/GEJ)腺癌的初步结果:一项单臂、多中心Ⅱ期临床试验
临床试验注册编号:NCT04891900
作者:中国河南,河南省肿瘤医院罗素霞教授团队 Ning Li
15. Abstract #376;Poster Bd #F17
题目:
Updated results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase Ⅱ clinical trial
紫杉醇和顺铂联合安罗替尼一线治疗晚期食管鳞状细胞癌(ESCC)患者的最新结果:一项多中心、单臂、开放标签的Ⅱ期临床试验
临床试验注册编号:NCT04063683
作者:中国河南,河南省肿瘤医院罗素霞教授团队 Ning Li
16. Abstract #377;Poster Bd #F18
题目:
Anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase Ⅱ clinical trial.
安罗替尼联合TQB2450 (PD-L1阻断剂)一线治疗晚期食管鳞癌(ESCC):一项单臂、多中心、开放标签期Ⅱ临床试验
临床试验注册编号:NCT05038813
作者:中国河南,南阳医学高等专科学校第一附属医院杨秀丽教授团队
17. Abstract #378;Poster Bd #F19
题目:
The efficacy and safety of neoadjuvant sintilimab combined with chemotherapy in elderly patients with locally advanced esophageal squamous cell carcinoma.
信迪利单抗联合化疗新辅助治疗局部晚期食管鳞状细胞癌老年患者的疗效和安全性
作者:中国河北,河北医科大学第四医院吕会来教授团队
18. Abstract #384;Poster Bd #G6
题目:
Camrelizumab plus apatinib for immunochemotherapy-treated advanced esophageal squamous cell carcinoma: Preliminary results of cohort 2 in CAP 02 study
卡瑞利珠单抗联合阿帕替尼的免疫化疗方案治疗晚期食管鳞状细胞癌:CAP 02研究队列2的初步结果
临床试验注册编号:NCT03736863
作者:中国河南,郑州大学第一附属医院樊青霞教授团队 王峰
19. Abstract #386;Poster Bd #G8
题目:
Adjuvant nab-paclitaxel plus S-1 versus oxaliplatin plus capecitabine after curative D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase 3 open-label, randomized controlled trial
Ⅲ期胃腺癌患者根治性D2胃切除术后接受辅助治疗白蛋白结合型-紫杉醇联合S-1 vs.奥沙利铂联合卡培他滨:一项3期开放标签、随机对照试验
临床试验注册编号:NCT04135781
作者:中国浙江,浙江省肿瘤医院程向东教授团队 俞鹏飞
20. Abstract #389;Poster Bd #G11
题目:
Efficacy of fecal microbiota transplantation in patients with anti-PD-1–resistant/refractory gastrointestinal cancers.
粪便微生物移植在抗PD-1耐药/难治性胃肠道癌症患者中的疗效
临床试验注册编号:NCT04130763
作者:中国北京,北京大学肿瘤医院沈琳教授团队 彭智
21. Abstract #395;Poster Bd #G17
题目:
A phase Ⅱ study of paclitaxel and carboplatin plus PD-1 inhibitors combined with anlotinib as first-line treatment for advanced esophageal cancer
紫杉醇和卡铂+ PD-1抑制剂联合安罗替尼一线治疗晚期食管癌的Ⅱ期研究
临床试验注册编号:NCT04471480
作者:中国重庆,陆军特色医学中心(大坪医院)李梦侠教授团队 许明芳
22. Abstract #396;Poster Bd #G18
题目:
Tislelizumab combined with anlotinib and chemotherapy (XELOX) in the treatment of advanced gastric carcinoma: Preliminary results of a single-arm, open-label phase I/Ⅱa trial (TALENT study).
替雷利珠单抗联合安罗替尼和化疗(XELOX)治疗晚期胃癌:单臂、开放标签I/Ⅱa期试验的初步结果(TALENT研究)
临床试验注册编号:NCT04963088
作者:中国江苏,南京医科大学第一附属医院束永前教授团队 陈晓锋
23. Abstract #402;Poster Bd #H5
题目:
An open-label, single-arm, dose escalation and expansion phase 1 study of tebotelimab (MGD013) plus niraparib in patients with locally advanced or metastatic gastric cancer who failed prior treatments.
tebotelimab(MGD013)联合尼拉帕利在既往治疗失败的局部晚期或转移性胃癌患者,一项开放标签、单臂、剂量递增和扩展的1期研究
临床试验注册编号:NCT04178460
作者:中国广东,中山大学肿瘤防治中心徐瑞华教授团队 邱妙珍
24. Abstract #409;Poster Bd #H12
题目:
Anlotinib combined with paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC).
安罗替尼联合紫杉醇和顺铂用于食管鳞状细胞癌(ESCC)的新辅助治疗
临床试验注册编号:ChiCTR2100054374
作者:中国河南,河南省胸科医院王国磊教授团队 姜功前
25. Abstract #410;Poster Bd #H13
题目:
Outcomes of transarterial chemoembolization in neoadjuvant therapy of patients with gastric cancer: A multicenter retrospective cohort study.
经动脉化疗栓塞术在胃癌患者新辅助治疗中的疗效:一项多中心回顾性队列研究
作者:中国重庆,重庆医科大学第一附属医院张伟教授团队 闵江
26. Abstract #415;Poster Bd #H18
题目:
Tumor microenvironment evaluation to predict anti–PD-1 response of advanced gastric cancer: Results from a multicenter prospective clinical trial.
肿瘤微环境评估用以预测晚期胃癌患者的抗PD-1预后:一项来自多中心、前瞻性临床试验的结果
临床试验注册编号:NCT#04850716
作者:中国广东,南方医科大学附属南方医院廖旺军教授团队
27. Abstract #417;Poster Bd #H20
题目:
Identification of HER2+ malignant cells in gastric tumors from single-cell RNAseq data.
单细胞RNAseq数据中识别胃肿瘤中HER-2阳性恶性细胞
作者:中国上海,欧易生物 Zhiming Zhang等
28. Abstract #442;Poster Bd #K8
题目:
Examination of antagonistic metabolic reactions and nicotinamide/methylnicotinamide as a biomarker in gastric cancer
胃癌中拮抗代谢反应和烟酰胺/甲基烟酰胺生物标志物的检查
作者:中国广东,南方医科大学附属南方医院廖旺军教授团队 石敏
肝胆胰肿瘤
1. Abstract #493;Poster Bd #A2
题目:
Adjuvant transarterial chemoembolization with sorafenib for patients with hepatocellular carcinoma with portal vein tumor thrombus after surgery: A phase III, multicenter, randomized, controlled trial.
经动脉化疗栓塞联合索拉非尼辅助治疗术后合并门静脉癌栓的肝细胞癌患者:一项III期、多中心、随机、对照试验
临床试验注册编号:NCT04143191
作者:中国广州,中山大学第一附属医院匡铭教授团队
2. Abstract #509;Poster Bd #A19
题目:
Comparison of anti–PD-L1 with anti–PD-1 antibodies in the combination of HAIC and lenvatinib for the treatment of unresectable hepatocellular carcinoma.
PD-L1抗体vs.PD-1抗体联合HAIC和仑伐替尼治疗不可切除肝细胞癌的比较
作者:中国广州,中山大学肿瘤防治中心郭荣平教授团队 李少华
3. Abstract #520;Poster Bd #B10
题目:
An active trend of immunotherapy combination regimen as second-line therapy for advanced biliary tract cancer: A multicenter retrospective study.
免疫治疗联合方案作为晚期胆道癌二线治疗的积极趋势:一项多中心回顾性研究
作者:中国浙江,浙江省肿瘤医院应杰儿教授团队
4. Abstract #530;Poster Bd #B20
题目:
Report of adverse events of special interest (AESIs) for sintilimab plus a bevacizumab biosimilar (IBI305) in unresectable hepatocellular carcinoma
信迪利单联合贝伐珠单抗生物类似物(IBI305)治疗不可切除肝细胞癌的特殊不良事件(AESIs)的报告
临床试验注册编号:NCT03794440
作者:中国上海,复旦大学附属中山医院樊嘉院士团队 任正刚
5. Abstract #544;Poster Bd #C14
题目:
Bevacizumab combined with atezolizumab or sintilimab as second-line treatment in patients with advanced hepatocellular carcinoma: A retrospective study
贝伐珠单抗联合阿替利珠单抗或信迪利单抗作为晚期肝细胞癌患者的二线治疗:一项回顾性研究
作者:中国天津,天津医科大学肿瘤医院宋天强教授团队 Leijuan Gan
6.Abstract #556;Poster Bd #D8
题目:
Safety of drug-eluting beads transarterial chemoembolization under the combination therapy with immune checkpoint inhibitors in unresectable hepatocellular carcinoma
药物洗脱珠经动脉化疗栓塞与免疫检查点抑制剂联合治疗不可切除肝细胞癌的安全性
作者:中国台湾,三军总医院Sung-Hua Chiu团队
7.Abstract #558;Poster Bd #D10
题目:
Efficacy and safety of envafolimab plus lenvatinib combined with TACE in unresectable hepatocellular carcinoma: An open-label, single-arm, phase 2 study—The CISLD-12 study
恩沃利单抗与仑伐替尼联合治疗不可切除肝细胞癌的疗效和安全性:一项开放标签、单臂、2 期研究——CISLD-12研究
临床试验注册编号:NCT05213221
作者:中国浙江,浙江大学医学院附属第一医院白雪莉教授团队 梁廷波
8. Abstract #564;Poster Bd #D16
题目:
Nab-paclitaxel plus anti–PD-1 antibody as second-line treatment for advanced biliary tract cancer: An investigator-initiated phase 2 study (NapaSinti trial)
白蛋白结合型紫杉醇加PD-1抗体作为晚期胆道癌的二线治疗:研究者发起的2期研究(NapaSinti试验)
临床试验注册编号:ChiCTR2100052118
作者:中国四川,四川大学华西医院勾红峰教授团队 Xiaofen Li
9.Abstract #567;Poster Bd #D19
题目:
A prospective single-arm phase Ⅱ study of blank-microsphere transarterial chemoembolization (bTACE) plus lenvatinib (LEN) and sequential microwave ablation (MWA) in patients with large hepatocellular carcinoma (L-HCC, ≥ 7 cm): The Talem trial
空白微球经动脉化疗栓塞术(bTACE)联合仑伐替尼(LEN)序贯微波消融术(MWA)治疗大肝细胞癌(L-HCC,≥7cm)的前瞻性单臂Ⅱ期研究:Talem 试验
临床试验注册编号:NCT05555316
作者:中国广东,中山大学肿瘤防治中心黄金华教授团队 Zhimei Huang
10. Abstract #568;Poster Bd #D20
题目:
Anlotinib plus toripalimab as first-line treatment for patients with unresectable hepatocellular carcinoma: Updated results of the ALTER-H003 trial
安罗替尼联合特瑞普利单抗作为不可切除肝细胞癌患者的一线治疗:ALTER-H003 试验的更新结果
临床试验注册编号:ChiCTR1900028295
作者:中国海南,海南医科大学第二附属医院林海锋教授团队
11. Abstract #570;Poster Bd #E2
题目:
ORIENT-32: Updated characterization of response to sintilimab plus bevacizumab biosimilar (IBI305) vs sorafenib for unresectable hepatocellular carcinoma
ORIENT-32:信迪利单抗加贝伐珠单抗生物类似药 (IBI305) vs.索拉非尼治疗不可切除肝细胞癌反应特征的更新数据
临床试验注册编号:NCT03794440
作者:中国上海,复旦大学附属中山医院樊嘉院士团队 任正刚
12.Abstract #571;Poster Bd #E3
题目:
A phase II clinical trial to study the use of cabozantinib (cabo) in patients with hepatocellular carcinoma (HCC) post immunotherapy treatment
一项Ⅱ期临床试验:旨在研究卡博替尼(cabo)在既往免疫治疗肝细胞癌(HCC)患者中的应用
临床试验注册编号:NCT04588051
作者:中国香港,Stephen Chan教授团队
13.Abstract #572;Poster Bd #E4
题目:
Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase Ⅱa dose-expansion study
高选择性不可逆的FGFR抑制剂Gunagratinib,用于既往经治局部晚期或转移性胆管癌患者的FGFR通路改变:一项Ⅱa期剂量扩展研究
临床试验注册编号:NCT03758664
作者:中国上海,同济大学附属东方医院李进教授团队 郭晔
14.Abstract #574;Poster Bd #E6
题目:
Sorafenib plus tislelizumab as maintenance therapy for patients with advanced hepatocellular carcinoma treated with transarterial chemoembolization: A phase Ⅱ study
索拉非尼联合替雷利珠单抗作为经动脉化疗栓塞治疗后晚期肝细胞癌患者的维持治疗:一项Ⅱ期研究
临床试验注册编号:NCT04599777
作者:中国广东,广州医科大学附属第二医院朱康顺教授团队 蔡明岳
15.Abstract #576;Poster Bd #E8
题目:
Tislelizumab in combination with anlotinib as first-line treatment for unresectable hepatocellular carcinoma: A single-arm, phase Ⅱ clinical trial
替雷利珠单抗联合安罗替尼作为不可切除肝细胞癌的一线治疗:一项单臂Ⅱ期临床试验
作者:中国广西,广西医科大学第一附属医院马劼教授团队 Shi-xue Laoguo
16.Abstract #577;Poster Bd #E9
题目:
Updated results from the phase Ⅱ study: Efficacy and safety of anlotinib plus sintilimab as second-line treatment for patients with advanced biliary tract cancers
Ⅱ期研究的更新结果:安罗替尼联合信迪利单抗作为晚期胆道癌患者二线治疗的疗效和安全性
临床试验注册编号:ChiCRT1900022003
作者:中国河南,郑州大学第一附属医院宗红教授团队 靳水玲
17. Abstract #578;Poster Bd #E10
题目:
Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and/or immunotherapy: An open-label, single-arm, phase 1/2 dose-escalation and expansion study
Tebotelimab 是一种 PD-1/LAG-3 双特异性抗体,用于既往靶向治疗和/或免疫治疗失败的晚期肝细胞癌患者:一项开放标签、单臂、1/2 期剂量递增和扩展研究
临床试验注册编号:NCT04212221
作者:中国上海,复旦大学附属中山医院任正刚教授团队
18. Abstract #581;Poster Bd #E13
题目:
Efficacy and safety of TACE combined with anlotinib compared with TACE alone among patients with intermediate or advanced hepatocellular carcinoma (HCC): A randomized, controlled, phase Ⅱclinical study
TACE 联合安罗替尼与单独 TACE 治疗中晚期肝细胞癌 (HCC) 患者的疗效和安全性:一项随机、对照、Ⅱ期临床研究
临床试验注册编号:NCT04066543
作者:浙江省肿瘤医院邵国良教授团队 曾晖
19.Abstract #583;Poster Bd #E15
题目:
Efficacy and safety of anlotinib with PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma: A real-world study
安罗替尼联合 PD-1 抑制剂治疗晚期肝细胞癌的疗效和安全性:一项真实世界研究
临床试验注册编号:NCT04954521
作者:中国广西,广西壮族自治区人民医院陈可和教授团队
20.Abstract #703;Poster Bd #K10
题目:
Camrelizumab combined with apatinib and albumin-bound paclitaxel followed by camrelizumab plus apatinib as first-line therapy for unresectable or metastatic pancreatic cancer
卡瑞利珠单抗联合阿帕替尼和白蛋白结合型紫杉醇序贯卡瑞利珠单抗联合阿帕替尼作为不可切除或转移性胰腺癌的一线治疗
临床试验注册编号:ChiCTR2100045844
作者:中国江苏,江苏省肿瘤医院沈波教授团队
21. Abstract #744;Poster Bd #M11
题目:
Patient-specific tumor-informed circulating tumor DNA (ctDNA) assay to predict cancer recurrence in patients with resected pancreatic cancer
患者个体化肿瘤知情(tumor-informed)循环肿瘤DNA(ctDNA)技术可预测胰腺癌切除患者的癌症复发
作者:中国天津,天津医科大学肿瘤医院郝继辉教授团队 王秀超
胃肠道间质瘤
1. Abstract #800;Poster Bd #M15
题目:
The efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: A multicenter, retrospective study
瑞派替尼在中国晚期胃肠道间质瘤患者中的疗效和安全性:一项多中心的回顾性研究
作者:中国浙江,浙江大学医学院附属第一医院于吉人教授团队 Weili Yang
2. Abstract #803;Poster Bd #M18
题目:
Efficacy and safety of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2 multicenter, randomized, open-label study in China.
瑞派替尼 vs. 舒尼替尼在既往接受伊马替尼治疗的晚期胃肠道间质瘤患者中的疗效和安全性:一项在中国进行的2期多中心、随机、开放标签研究
临床试验注册编号:NCT04633122
作者:中国北京,北京大学肿瘤医院沈琳教授团队 李健
以上Poster研究PI里
是否有你熟悉的专家?
快在留言区评论打call吧!
(如有错误,欢迎指正)
排版编辑:肿瘤资讯-Bree